Aerie Pharmaceuticals Inc (AERI) Peer Comparison
$15.25
$0.00 (0.00%)As on 22-Nov-2022 09:30EDT
Market cap
$754 Mln
Revenue (TTM)
$214 Mln
P/E Ratio
--
P/B Ratio
34.3
Div. Yield
0 %
Edit
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
754 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
214 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-36.56 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-17.80 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-- | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 264.84 | -- | -- |
Price-To-Book |
34.26 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
213.94 | 69.72 | 365.98 | 4,764.00 | 8.82 |
|
Cost of Revenue
|
23.52 | 3.11 | 5.28 | 2,688.00 | 1.16 |
|
Gross Profit
|
167.29 | 66.60 | 360.70 | 2,076.00 | -1.16 |
|
Operating Expenses
|
217.13 | 643.23 | 236.22 | 1,772.00 | 124.71 |
|
Operating Profit (EBIT)
|
-26.71 | -576.63 | 124.48 | 304.00 | -124.71 |
|
Other Income
|
-8.52 | 36.96 | 0.53 | -5.00 | -5.70 |
|
Profit before Tax
|
-35.23 | -586.45 | 125.01 | -571.00 | -130.40 |
|
Provision for Tax
|
1.32 | 52.84 | 12.49 | -88.00 | 4.54 |
|
Profit after Tax (Net Income)
|
-36.56 | -562.54 | 112.51 | -483.00 | -134.94 |
|
Minority Interest
|
0.00 | 3.41 | -- | -- | -- |
|
Consolidated Profit
|
-36.56 | -562.54 | 112.51 | -472.00 | -130.40 |
Liabilities ($ Mln)
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-163.98 | -870.41 | 375.81 | 7,508.00 | 15.63 |
|
Minority Interest
|
0.00 | 3.41 | -- | -- | -- |
|
Non-Current Liabilities
|
406.24 | 1,743.30 | 0.41 | 7,323.00 | 49.09 |
|
Current Liabilities
|
133.33 | 135.07 | 47.54 | 1,647.00 | 23.07 |
|
Total Liabilities
|
431.39 | 1,012.79 | 423.76 | 16,478.00 | 87.79 |
Assets ($ Mln)
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
72.78 | 123.93 | 157.29 | 13,204.00 | 1.27 |
|
Current Assets
|
302.81 | 888.86 | 266.46 | 3,274.00 | 86.52 |
|
Total Assets
|
431.39 | 1,012.79 | 423.76 | 16,478.00 | 87.79 |
|
Total Debt*
|
336.99 | 1,726.17 | 0.53 | 6,319.00 | 49.71 |
|
Net Current Assets
|
169.48 | 709.58 | 218.92 | 1,633.00 | 63.45 |
Cashflow ($ Mln)
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-99.15 | -497.93 | 167.89 | 483.00 | -108.23 |
|
Cash Flow from Investing Activities
|
-18.20 | -200.83 | 136.13 | -530.00 | -0.31 |
|
Cash from Financing Activities
|
2.97 | 736.45 | -302.59 | 210.00 | 11.13 |
|
Net Cash Inflow / Outflow
|
-114.38 | 37.69 | 1.43 | 163.00 | -97.40 |
Ratios
Profitability Ratios
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-31.00 | -79.82 | 24.94 | -3.40 | -117.72 |
|
ROE (%)
|
-2,255.01 | 138.47 | 25.03 | -6.04 | -208.53 |
|
ROA (%)
|
-7.47 | -65.55 | 22.60 | -2.83 | -98.53 |
|
EBIT Margin (%)
|
-10.86 | -- | -- | -- | -- |
|
Net Margin (%)
|
-17.80 | -527.35 | 30.70 | -10.15 | -4,319.95 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
105.41 | 7.45 | 0.03 | 0.46 | -- |
|
EBIT Growth (%)
|
82.50 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
78.04 | -25.36 | 6.13 | 13.77 | -31.14 |
|
EPS Growth (%)
|
80.10 | -0.03 | 0.10 | 0.14 | -0.30 |
|
Book Value Growth (%)
|
-115.64 | -- | -- | -- | -- |
Valuation Ratios
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-4.32 | -4.31 | 21.55 | -28.64 | -10.57 |
|
Price / Book Value
|
-18.63 | -2.78 | 6.45 | 1.84 | 91.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-56.80 | -6.21 | 17.26 | 47.71 | -11.25 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.91 | -1.98 | 0.00 | 0.84 | 3.18 |
|
Short term debt to equity ratio
|
-0.03 | -0.01 | 0.00 | 0.04 | 0.04 |
|
Current Ratio
|
2.27 | 6.58 | 5.60 | 1.99 | 3.75 |
|
Quick Ratio
|
1.92 | 7.09 | 5.50 | 1.16 | 3.75 |
|
Interest Coverage
|
-1.94 | -11.54 | 34.62 | -1.16 | -21.89 |
Operating Efficiency Ratios
| Aerie Pharmaceuticals Inc (AERI) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
34.53 | 28.33 | 7.93 | 21.58 | 0.00 |
|
Asset Turnover
|
0.44 | 0.08 | 0.74 | 0.28 | 0.06 |
|
Receivable days
|
202.11 | 103.47 | 27.56 | 80.69 | 0.00 |
|
Inventory Days
|
458.97 | -8,081.13 | 904.13 | 200.36 | 0.00 |
|
Payable days
|
116.40 | 1,221.55 | 603.86 | 62.30 | 4,211.93 |
|
Cash Conversion Cycle
|
544.68 | -9,199.21 | 327.83 | 218.75 | -4,211.93 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
